Inflammatory Biomarkers and Atherosclerosis

Soeki, Takeshi; Sata, Masataka

doi:10.1536/ihj.15-346

Cited by 141 publications

(108 citation statements)

References 53 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…9,10) However, very few reports have described a link between statins and sPLA2-IIA expression. Menschikowski, et al found that the expression of sPLA2-IIA in human aorta smooth muscle cells (HASMC) can be increased by statins, and this effect is based on both bJak2-, C/EBP-h-and NF-κB-dependent transcriptional regulation and the stabilization of sPLA2-IIA mRNA.…”

Section: Discussionmentioning

confidence: 99%

“…6,7) Indeed, statins can increase the stability of atherosclerotic plaques by increasing the release of vascular endothelial nitric oxide, 8) improving vascular smooth muscle cell adhesion/migration, and promoting a T helper 2 bias and suppressing the secretion of T helper 1 cytokines. 3) Recently, more and more gene products have been shown to be regulated by statins, such as cyclooxygenase2, 9) inducible nitric oxide (NO) synthase, tumor necrosis factor (TNF), and interleukin (IL)-6, 10) which play a role in inflammation and atherosclerosis.…”

mentioning

confidence: 99%

See 1 more Smart Citation

Effects of Statins and Xuezhikang on the Expression of Secretory Phospholipase A2, Group IIA in Rat Vascular Smooth Muscle Cells

Xie

Zhang²

2017

Int. Heart J.

View full text Add to dashboard Cite

SummaryAtherosclerosis is a multifactorial vascular disease characterized by formation of inflammatory lesions. Secretory phospholipase A2, group IIA (sPLA2-IIA) is involved in this process and plays a critical role. However, the exact role of sPLA2-IIA in cardiovascular inflammation is more complicated and remains unclear. Furthermore, both statins and Xuezhikang (XZK) are widely used in the prevention and treatment of cardiovascular disease risk because of their pleiotropic effects on the cardiovascular system. However, their effects on sPLA2-IIA are still controversial. We investigated the regulation of sPLA2-IIA by rat thoracic aorta smooth muscle cells (VSMCs) in culture. Cells were first incubated with IL-1β alone to induce expression of sPLA2-IIA and then treated with several concentrations of statins or XZK for different times in the absence or presence of IL-1β. We tested the expression of sPLA2-IIA, including sPLA2-IIA mRNA, protein, as well as activity. We found that statins or IL-1β increase the expression of sPLA2-IIA in VSMCs and the effect is based on a synergetic relationship between them. However, for the first time, we observed that XZK effectively reduces sPLA2-IIA expression in IL-1β-treated VSMCs. Our findings may shine a new light on the clinical use of XZK and statins in the prevention and treatment of atherosclerosis-related thrombosis. (Int Heart J 2017; 58: 115-124)

show abstract

Section: Discussionmentioning

confidence: 99%

mentioning

confidence: 99%

Effects of Statins and Xuezhikang on the Expression of Secretory Phospholipase A2, Group IIA in Rat Vascular Smooth Muscle Cells

Xie

Zhang²

2017

Int. Heart J.

View full text Add to dashboard Cite

show abstract

“…1) Given this unfulfilled need for effective treatment, there is augmenting interest in targeting a novel pathway, inflammation, that underlies CAD and its risk factors. [2][3][4] Further, gut microbiota, which contribute to metabolism and immunity, are current topics as diagnostic and therapeutic targets of CAD. 5,6) The role of gut microbiota in common diseases has been explored mainly due to technical advances such as the use of next generation sequencing to profile samples including fecal microbial DNA together with the development of bioinformatics technology.…”

Section: Oronary Artery Disease (Cad) Is a Growing Epidemic Inmentioning

confidence: 99%

Gut Microbiota and Coronary Artery Disease

et al. 2016

View full text Add to dashboard Cite

SummaryGut microbiota have been attracting increased attention in many fields of medicine recently. We can perform a comprehensive analysis of gut microbiota using next-generation sequencing techniques together with bioinformatics technology, which expands our knowledge of a large ecosystem consisting of a host and gut microbiota. We summarize some reports about the correlations between gut microbiota and metabolic disorders, particularly atherosclerosis, and discuss future directions for the diagnostic or therapeutic potential of gut microbiota. To take simple examples, we demonstrated that the order Lactobacillales was significantly increased; while the phylum Bacteroidetes was significantly decreased in coronary artery disease (CAD) patients compared with controls or healthy volunteers. The characteristics of gut microbiota in type 2 diabetes and dyslipidemia have been reported. However, these studies have limitations, and the biological significance of gut microbiota and the causal relationships are still controversial. We hope the reports listed in this review article might lead to the development of a novel therapy to prevent CAD via modulating gut microbiota or their metabolites. (Int Heart J 2016; 57: 663-671)

show abstract

“…1,2) It leads to the narrowing of coronary arteries, which is often asymptomatic early in the course of the disease, but progresses with plaque thickening or plaque rupture, ultimately leading to angina and/or myocardial infarction. [3][4][5][6] The consequences of atherosclerosis represent the most important cause of death in the United States, where the prevalence of atherosclerosis is approximately 6.2% in people > 20 years of age.…”

mentioning

confidence: 99%

High-Sensitivity C-Reactive Protein Combined with Low-Density Lipoprotein Cholesterol as the Targets of Statin Therapy in Patients with Acute Coronary Syndrome

Fang

Qian²,

Zhao³

et al. 2018

Int. Heart J.

View full text Add to dashboard Cite

SummaryTo investigate the combination of high-sensitivity C-reactive protein (hs-CRP) and Low-density lipoprotein (LDL)-C as the targets for statin treatment in patients with acute coronary syndrome (ACS). This single-center, prospective, randomized study was performed in 400 patients treated with atorvastatin 40 mg/day for 1 month and then with atorvastatin 20 mg/day as maintenance. The patients were randomized to the LDL group (LDL-C target of < 2.07 mmol/L according to the Chinese dyslipidemia guidelines) and to the LDL-CRP group (LDL-C target of < 2.07 mmol/L and hs-CRP target of < 3 mg/L). The patients were followed up for major adverse cardiac events (MACE) at 6, 12, and 18 months. The two groups had similar baseline characteristics and 391 patients completed the follow-up. No differences were found in LDL-C between the two groups, but a difference was found in hs-CRP at 12 and 18 months. There was a significant difference in revascularization (8.7% versus 3.6%, P = 0.04) and MACE (16.8% versus 9.7%; P = 0.04) between the LDL and LDL-CRP groups at 18 months. Compared to LDL-C as the single target, targeting both LDL-C and hs-CRP by statin therapy in patients with ACS could further reduce the incidence of MACE and the residual cardiovascular risk.(Int Heart J Advance Publication)

show abstract

Inflammatory Biomarkers and Atherosclerosis

Cited by 141 publications

References 53 publications

Effects of Statins and Xuezhikang on the Expression of Secretory Phospholipase A2, Group IIA in Rat Vascular Smooth Muscle Cells

Effects of Statins and Xuezhikang on the Expression of Secretory Phospholipase A2, Group IIA in Rat Vascular Smooth Muscle Cells

Gut Microbiota and Coronary Artery Disease

High-Sensitivity C-Reactive Protein Combined with Low-Density Lipoprotein Cholesterol as the Targets of Statin Therapy in Patients with Acute Coronary Syndrome

Contact Info

Product

Resources

About